TTY Biopharm Company Limited

TPEX:4105 Stock Report

Market Cap: NT$20.3b

TTY Biopharm Future Growth

Future criteria checks 0/6

TTY Biopharm is forecast to grow earnings and revenue by 0.3% and 8.4% per annum respectively while EPS is expected to grow by 0.3% per annum.

Key information

0.3%

Earnings growth rate

0.27%

EPS growth rate

Pharmaceuticals earnings growth148.5%
Revenue growth rate8.4%
Future return on equityn/a
Analyst coverage

Low

Last updated27 Nov 2025

Recent future growth updates

Recent updates

Here's Why TTY Biopharm (GTSM:4105) Can Manage Its Debt Responsibly

Apr 02
Here's Why TTY Biopharm (GTSM:4105) Can Manage Its Debt Responsibly

Is There An Opportunity With TTY Biopharm Company Limited's (GTSM:4105) 43% Undervaluation?

Mar 15
Is There An Opportunity With TTY Biopharm Company Limited's (GTSM:4105) 43% Undervaluation?

Are Dividend Investors Making A Mistake With TTY Biopharm Company Limited (GTSM:4105)?

Feb 25
Are Dividend Investors Making A Mistake With TTY Biopharm Company Limited (GTSM:4105)?

TTY Biopharm Company Limited (GTSM:4105) Stock's Been Sliding But Fundamentals Look Decent: Will The Market Correct The Share Price In The Future?

Feb 07
TTY Biopharm Company Limited (GTSM:4105) Stock's Been Sliding But Fundamentals Look Decent: Will The Market Correct The Share Price In The Future?

TTY Biopharm Company Limited (GTSM:4105) Analysts Just Cut Their EPS Forecasts Substantially

Jan 19
TTY Biopharm Company Limited (GTSM:4105) Analysts Just Cut Their EPS Forecasts Substantially

What Type Of Returns Would TTY Biopharm's(GTSM:4105) Shareholders Have Earned If They Purchased Their SharesFive Years Ago?

Jan 10
What Type Of Returns Would TTY Biopharm's(GTSM:4105) Shareholders Have Earned If They Purchased Their SharesFive Years Ago?

TTY Biopharm (GTSM:4105) Has A Pretty Healthy Balance Sheet

Dec 15
TTY Biopharm (GTSM:4105) Has A Pretty Healthy Balance Sheet

How Does TTY Biopharm Company Limited (GTSM:4105) Fare As A Dividend Stock?

Nov 25
How Does TTY Biopharm Company Limited (GTSM:4105) Fare As A Dividend Stock?

Earnings and Revenue Growth Forecasts

TPEX:4105 - Analysts future estimates and past financials data (TWD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/20267,1571,760N/AN/A1
12/31/20256,4901,6831,3341,4141
9/30/20256,5031,7901,6101,784N/A
6/30/20256,2161,5831,4101,564N/A
3/31/20256,0791,5601,2441,396N/A
12/31/20245,8941,4501,2151,349N/A
9/30/20245,8261,1201,0171,122N/A
6/30/20245,7261,1249821,087N/A
3/31/20245,6131,1711,0991,211N/A
12/31/20235,5061,1299861,085N/A
9/30/20235,3941,168758891N/A
6/30/20235,2871,1301,0911,219N/A
3/31/20235,1911,1061,0211,142N/A
12/31/20225,0621,0941,1001,236N/A
9/30/20224,9971,1931,2941,399N/A
6/30/20224,7311,1091,0151,116N/A
3/31/20224,6098561,1561,247N/A
12/31/20214,5368321,1821,256N/A
9/30/20214,270751873937N/A
6/30/20214,235720768937N/A
3/31/20214,092874444619N/A
12/31/20204,222924344526N/A
9/30/20204,130693455646N/A
6/30/20204,255787894980N/A
3/31/20204,4458601,1231,191N/A
12/31/20194,4669001,1391,210N/A
9/30/20194,4471,2361,2411,298N/A
6/30/20194,2041,263N/A980N/A
3/31/20194,1101,499N/A893N/A
12/31/20184,0361,461N/A1,074N/A
9/30/20184,1021,696N/A1,013N/A
6/30/20184,2401,631N/A1,099N/A
3/31/20184,1731,379N/A1,237N/A
12/31/20174,0791,345N/A997N/A
9/30/20173,8741,088N/A980N/A
6/30/20173,7651,023N/A1,031N/A
3/31/20173,7951,134N/A1,109N/A
12/31/20163,7611,193N/A1,227N/A
9/30/20163,7331,536N/A1,083N/A
6/30/20163,6121,565N/A938N/A
3/31/20163,3891,393N/A947N/A
12/31/20153,1951,211N/A639N/A
9/30/20153,0581,133N/A698N/A
6/30/20152,929986N/A725N/A
3/31/20152,969829N/A593N/A
12/31/20142,980780N/A578N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: 4105's forecast earnings growth (0.3% per year) is below the savings rate (1.2%).

Earnings vs Market: 4105's earnings (0.3% per year) are forecast to grow slower than the TW market (20.5% per year).

High Growth Earnings: 4105's earnings are forecast to grow, but not significantly.

Revenue vs Market: 4105's revenue (8.4% per year) is forecast to grow slower than the TW market (14.2% per year).

High Growth Revenue: 4105's revenue (8.4% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if 4105's Return on Equity is forecast to be high in 3 years time

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/12/01 09:42
End of Day Share Price 2025/12/01 00:00
Earnings2025/09/30
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

TTY Biopharm Company Limited is covered by 8 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Christine WangDaiwa Securities Co. Ltd.
Caren HuangJ.P. Morgan
Yu-Ying YangKGI Securities Co. Ltd.